Latest News

• 27 Jan 2021 – Destiny Pharma welcomes Matt Hancock’s statement saying G7 will focus on AMR
• 21 Jan 2021 – Destiny Pharma Investor Presentation
• 06 Jan 2021 – Destiny Pharma appoints Stephanie Bewick as Chief Business Officer
• 05 Jan 2021 – Phase 2b trial of XF-73 completes recruitment
• 22 Dec 2020 – Update on the recently acquired NTCD-M3 programme
• 21 Dec 2020 – Destiny Pharma joins the Pharmabiotic Research Institute (PRI)
• 26 Nov 2020 – Destiny Pharma – Result of General Meeting and Total Voting Rights
• 25 Nov 2020 – Destiny Pharma announces total gross proceeds raised via Open Offer
• 18 Nov 2020 – Antibiotic Resistance: A Matter of Time – FT
• 09 Nov 2020 – Destiny Pharma to acquire Phase 3 ready C.difficile program and announces fund raising